FDA Speeds Up Cancer Drug Approvals with New Testing Tricks
Published Date: 1/21/2026
Notice
Summary
The FDA is rolling out new draft guidance to help drug makers use special tests called minimal residual disease (MRD) and complete response (CR) to speed up approval of multiple myeloma treatments. This means patients with this blood cancer could get access to promising drugs faster. Industry folks should send their feedback by March 23, 2026, so the FDA can finalize the rules and keep innovation moving without unnecessary delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Faster access to myeloma treatments
If you have multiple myeloma, the FDA's draft guidance says sponsors may use minimal residual disease (MRD) negativity and complete response (CR) as primary endpoints to support accelerated approval. That could allow promising multiple myeloma drugs to reach patients faster than traditional endpoints.
Clear trial road map for drug sponsors
If you are a drug sponsor, the FDA's draft guidance provides recommendations on using MRD and CR as primary endpoints to support accelerated approval and includes trial design, statistical, and assay considerations. The Agency requests comments on the draft by March 23, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-01067, Advisory Committee on the Readjustment of Veterans, Notice of Meeting
The Advisory Committee on the Readjustment of Veterans will meet online on March 24, 2026, to review their latest report and plan future meetings. This group helps the VA improve benefits and services for Veterans adjusting to civilian life, especially those who served in combat. The public can join, share comments, and help shape how Veterans get support—no money changes announced, but your voice matters!
Next: 2026-01069, Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability
The FDA just gave the green light for certain medical devices to be used during the COVID-19 emergency. This means doctors and hospitals can use these devices faster to help fight the virus, keeping everyone safer. These authorizations started as soon as they were issued, making sure help arrives right when it’s needed most.